Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with...
You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...
It has long been known that a calorierestricted diet can help prevent the conditions frequently associated withaging. However, many doctors and scientists are reluctant to recommend acaloric intake as low as is required as this may also lead to inadequatenutrition which, in turn, can cause other problems. Recent...
LONDON, PHILADELPHIA and CAMBRIDGE, Mass., June 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that it has completed its acquisition of Sirtris Pharmaceuticals, Inc. Sirtris for approximately USD720 million (or approx. GBP362 million) through a cash tender offer and merger of USD22.50 (or approx. GBP11.33) per share....
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the American Diabetes Association's 68th Annual Scientific Sessions in San Francisco. Peter...
Business News IN BRIEF *Fountain Acquisition Corp-oration FAC, a subsidiary of GlaxoSmithKline, has completed the tender offer for the US-based Sirtris Pharmaceuticals. The tender, worth about 362m, will see GSK take control of the Nasdaq-listed biotechnology group that specialises in developing drugs to fight age-related conditions such...
LONDON and PHILADELPHIA, June 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc announced today the successful completion of the tender offer by its wholly-owned subsidiary Fountain Acquisition Corporation FAC for shares of common stock of Sirtris Pharmaceuticals, Inc. . The depositary for the offer has advised GSK and FAC...
NEW YORK, June 2 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the following changes effective on the opening of trading on Thursday, June 5, 2008: NeuroSearch AS (Copenhagen: NEUR) will replace Sirtris...
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it reported its consolidated financial results for the quarter ended March 31, 2008. First Quarter 2008 Financial Results Unaudited ...
Bio-IT World magazine today announced thewinners of its fourth Best Practices Awards program. Grand Prize winnerswithin seven life sciences awards categories include Applied Biosystems,Christian-Albrechts-University, Eli Lilly & Company, GlaxoSmithKline,Genstruct, Sirtris Pharmaceuticals, AstraZeneca, and Merck & Company. Established in 2003, Bio-IT World's Best Practices Awards Programrecognizes these organizations for their...
Realized gain underlines Hercules' continued liquidity amid uncertain market conditions PALO ALTO, Calif. -- Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), the premier specialty finance company providing venture debt and equity to venture capital and private equity backed technology and life science companies at all stages of development, today...
Business News IN BRIEF *GlaxoSmithKline, the UK's biggest drug maker, is paying $720m for an early-stage US biotech company that promises to unlock the secrets of ageing. Sirtris Pharmaceuticals, based in Cambridge, Massachusetts, is working on sirtuins, a recently discovered type of enzyme linked to the ageing...
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of...
Clinical Trial Further Demonstrates Efficacy of SIRT1 Activation In Humans CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, today announced positive top-line data from its twice-daily dosing...
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that a research team led by the company's two Scientific Advisory Board co-chairs has demonstrated that overexpression of the SIRT1 enzyme can suppress tumor formation...
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that the United States Food and Drug Administration has granted the company orphan-drug designation for resveratrol in the treatment of MELAS syndrome (Mitochondrial myopathy, encephalopathy,...
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the American Chemical Society annual meeting in New Orleans on Monday, April 7 at...
Presentations Will Take Place at the Pasteur Institute, March 28 and the British Societies for Cell and Developmental Biology at the University of Warwick, March 31 CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases...
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that Paul A. Friedman, M.D., President and CEO of Incyte Corporation, has been appointed to its Board of Directors....
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the BioCentury/Thomson Financial 15th Annual Future Leaders in the Biotechnology Industry Conference on Thursday,...
CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that the United States Patent Office issued to Sirtris the first patent covering a broad class of compounds that...
Articles 2008-03-19
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Enjoy season-long live scoring and stats in CBSSports.com Free Fantasy Football
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
